tucidinostat/celecoxib (CC-02) / GNT Biotech - LARVOL DELTA

[Announcement] GNTbm-CC-02, a new dosage form of fluorobenamide salt independently developed by Huashang Biomedical, has obtained a Russian invention patent after review [Google translation] (stock.yahoo) - "GNTbm-CC-02, a new dosage form of fluorobenamide salt independently developed by Huashang Biomedical, has obtained a Russian invention patent after review...the patent...application number: 2022109453....GNTbm-CC-02, a new dosage form of fluorobenzamide salts independently developed by our company, is produced by Tucidinostat/salt + Celecoxib/salt, which can be used alone or in combination. It is a tumor microbiome."

Patent • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer